Evaluation of the serum matrix metalloproteinase-9 as a biomarker for monitoring disease progression in Duchenne muscular dystrophy

Neuromuscular Disorders

Volumn 25, Issue 5, 2015, Pages 444-446

  Zocevic, Aleksandar ^a   Rouillon, Jeremy ^a   Wong, Brenda ^b   Servais, Laurent ^c   Voit, Thomas ^d,e   Svinartchouk, Fedor ^a  

^a GÉNÉTHON   (France)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c Institut de Myologie   (France)

^d CNRS   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CORTICOSTEROID; GELATINASE B;

ADULT; AGE; CHILD; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; DISEASE COURSE; DUCHENNE MUSCULAR DYSTROPHY; ENZYME BLOOD LEVEL; HUMAN; LETTER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN DETERMINATION; ANIMAL; BLOOD; FEMALE; MALE; PATHOPHYSIOLOGY;

ANIMALS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MUSCULAR DYSTROPHY, DUCHENNE;

EID: 84927909388     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2015.01.010     Document Type: Letter

References (1)

1. Nadarajah V.D., van Putten M., Chaouch A., et al. Serum matrix metalloproteinase-9 (MMP-9) as a biomarker for monitoring disease progression in Duchenne muscular dystrophy (DMD). Neuromuscul Disord 2011, 21:569-578.